The University of Chicago Header Logo

Connection

Benjamin Derman to Humans

Back to Details
This is a "connection" page, showing publications Benjamin Derman has written about Humans.
Benjamin Derman
Connection Strength
0.864
Humans
  1. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
    View in: PubMed
    Score: 0.032
  2. Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 Sep 06; 29(9):806-810.
    View in: PubMed
    Score: 0.032
  3. Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
    View in: PubMed
    Score: 0.032
  4. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
    View in: PubMed
    Score: 0.031
  5. Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):477-495.
    View in: PubMed
    Score: 0.030
  6. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.
    View in: PubMed
    Score: 0.030
  7. MRD-guided treatment cessation in multiple myeloma. Lancet Haematol. 2023 11; 10(11):e867-e868.
    View in: PubMed
    Score: 0.030
  8. Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies. Eur J Cancer. 2023 08; 189:112926.
    View in: PubMed
    Score: 0.029
  9. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.
    View in: PubMed
    Score: 0.028
  10. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
    View in: PubMed
    Score: 0.028
  11. Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108.
    View in: PubMed
    Score: 0.027
  12. Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.
    View in: PubMed
    Score: 0.027
  13. When a Monoclonal Gammopathy Is Not Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-10.
    View in: PubMed
    Score: 0.027
  14. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. Blood Rev. 2022 05; 53:100913.
    View in: PubMed
    Score: 0.027
  15. Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. JAMA. 2021 Sep 21; 326(11):1058-1059.
    View in: PubMed
    Score: 0.026
  16. Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887.
    View in: PubMed
    Score: 0.026
  17. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
    View in: PubMed
    Score: 0.025
  18. Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69.
    View in: PubMed
    Score: 0.024
  19. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
    View in: PubMed
    Score: 0.024
  20. Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO Oncol Pract. 2021 03; 17(3):e445-e453.
    View in: PubMed
    Score: 0.024
  21. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
    View in: PubMed
    Score: 0.024
  22. Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.
    View in: PubMed
    Score: 0.024
  23. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).
    View in: PubMed
    Score: 0.023
  24. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
    View in: PubMed
    Score: 0.023
  25. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020 03; 61(3):614-622.
    View in: PubMed
    Score: 0.023
  26. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? Best Pract Res Clin Haematol. 2019 12; 32(4):101102.
    View in: PubMed
    Score: 0.023
  27. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.019
  28. Bendamustine-induced nephrogenic diabetes insipidus?. Clin Nephrol. 2017 Jan; 87 (2017)(1):47-50.
    View in: PubMed
    Score: 0.019
  29. Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective Analysis. Semin Thromb Hemost. 2015 Jul; 41(5):503-13.
    View in: PubMed
    Score: 0.017
  30. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
    View in: PubMed
    Score: 0.008
  31. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 Aug; 25(8):e374-e387.
    View in: PubMed
    Score: 0.008
  32. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
    View in: PubMed
    Score: 0.008
  33. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216.
    View in: PubMed
    Score: 0.008
  34. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 01; 22(1D):e240001.
    View in: PubMed
    Score: 0.008
  35. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
    View in: PubMed
    Score: 0.007
  36. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802.
    View in: PubMed
    Score: 0.007
  37. Endocrine Society Hypercalcemia of Malignancy Guidelines. JAMA Oncol. 2023 03 01; 9(3):430-431.
    View in: PubMed
    Score: 0.007
  38. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
    View in: PubMed
    Score: 0.007
  39. Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. J Hematol Oncol. 2022 08 16; 15(1):106.
    View in: PubMed
    Score: 0.007
  40. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.007
  41. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
    View in: PubMed
    Score: 0.006
  42. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Adv. 2020 10 13; 4(19):4924-4928.
    View in: PubMed
    Score: 0.006
  43. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
    View in: PubMed
    Score: 0.006
  44. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020 06 23; 4(12):2810-2820.
    View in: PubMed
    Score: 0.006
  45. A small field for fertile science: the low visibility of reproductive science in high impact journals. J Assist Reprod Genet. 2014 May; 31(5):511-20.
    View in: PubMed
    Score: 0.004
  46. Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Women's Health Initiative observational study. Breast Cancer Res Treat. 2013 Jun; 139(3):821-31.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.